-
Nat Biotech: Producing 1 billion CAR-T cells at a time, the new CRISPR technology efficiently
Time of Update: 2022-09-20
In this latest study, the research team developed a new CRISPR system that utilizes a single-stranded DNA (ssDNA) HDR template (HDRT) that binds to the Cas9 target sequence to achieve 2-3 times the knock-in efficiency and yield relative to dsDNA.
-
Nat Biotech: New implantable stent more effective than CAR-T therapy
Time of Update: 2022-04-25
First author Pritha Agarwalla, a postdoctoral researcher in the Joint Department of Biomedical Engineering, said: "Our MASTER technology transfers the tedious and time-consuming steps of activation, reprogramming and amplification to the patient .
-
Genxi Biotech will announce the results of preclinical research on the treatment of B-cell
Time of Update: 2021-11-14
Suzhou, Shanghai, China and Palo Alto, California, USA November 4, 2021/PRNewswire/ - Genxi Biotech Group (NASDAQ: GRCL; referred to as "Genxi Bio") is committed to A global clinical-stage biopharmace
-
The BCMA CAR-T jointly developed by Cinda Biotech and Reindeer Medical was approved
Time of Update: 2021-07-26
Cinda Biopharmaceuticals and Reindeer Medical jointly announced today that the fully human BCMA chimeric antigen receptor autologous T cell injection (Cinda Biologics R&D code: IBI326; Reindeer Medical R&D code: CT103A) jointly developed by both parties has passed the National Drug Supervision During the publicity period of the Center for Drug Evaluation (CDE) of the National Administration of Management (NMPA), the "breakthrough treatment drug variety" is included, and the proposed indication is relapsed/refractory multiple myeloma (R/R MM) .
-
Proton Biotech announced that it has reached a strategic cooperation with Kaidi Biotech to accelerate the development and production of CAR-T drugs
Time of Update: 2021-07-06
According to the agreement, Proton Bio will serve as the exclusive CDMO partner to provide CMC research and development services for multiple CAR-T projects, including the process development and production of plasmids, viral vectors and CAR-T cells, and the IND registration of the CMC part.
-
Maoxing Biotech's new CAR-T treatment of glioma has made breakthroughs in clinical research | Yimai Meng broke the news
Time of Update: 2021-05-22
Shang Xiaoyun, founder and CEO of Maoxing Biotechnology, the company's new CAR-T cells have achieved such breakthrough results in solid tumors, mainly due to the following three points: (1) Allogeneic universal CAR-T technology: this The core raw material of the product-T cells are collected from healthy volunteers.
-
The third-generation CAR-T of Mustang Biotech obtains US FDA approval for IND application to initiate clinical research | Yimai Meng broke the news
Time of Update: 2021-05-21
Initiated phase 1/2 clinical research to develop the safety, tolerability and safety of MB-106 for the treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL) Effectiveness.